Handelsbanken Fonder AB Grows Holdings in Illumina, Inc. (NASDAQ:ILMN)

Handelsbanken Fonder AB grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 92,330 shares of the life sciences company’s stock after purchasing an additional 16,050 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.06% of Illumina worth $12,338,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ILMN. Creative Planning grew its stake in Illumina by 3.3% in the 3rd quarter. Creative Planning now owns 16,679 shares of the life sciences company’s stock worth $2,175,000 after acquiring an additional 535 shares in the last quarter. Sequoia Financial Advisors LLC boosted its holdings in shares of Illumina by 6.6% in the third quarter. Sequoia Financial Advisors LLC now owns 4,944 shares of the life sciences company’s stock valued at $645,000 after purchasing an additional 307 shares during the period. Greenleaf Trust grew its stake in Illumina by 7.9% in the third quarter. Greenleaf Trust now owns 4,659 shares of the life sciences company’s stock worth $608,000 after purchasing an additional 341 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Illumina by 196.6% during the 3rd quarter. International Assets Investment Management LLC now owns 45,383 shares of the life sciences company’s stock worth $59,180,000 after purchasing an additional 30,080 shares during the period. Finally, IFM Investors Pty Ltd raised its position in Illumina by 1.2% during the 3rd quarter. IFM Investors Pty Ltd now owns 32,372 shares of the life sciences company’s stock valued at $4,222,000 after purchasing an additional 385 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Shares of ILMN stock opened at $94.20 on Friday. Illumina, Inc. has a fifty-two week low of $93.50 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a market capitalization of $14.92 billion, a price-to-earnings ratio of -12.27, a PEG ratio of 1.60 and a beta of 1.10. The stock’s 50-day simple moving average is $127.98 and its 200-day simple moving average is $134.13.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ILMN shares. Royal Bank of Canada dropped their price target on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. increased their target price on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Guggenheim cut their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and lowered their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Morgan Stanley dropped their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.